Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Triple-negative breast carcinoma (TNBC) is an aggressive cancer subtype with limited targeted therapy options.
• TNBC's biological heterogeneity poses challenges for developing effective treatments.
• There is a critical need for novel therapeutic strategies targeting TNBC.

Purpose of the Study:

• To develop and evaluate a TNBC-specific targeted nano-delivery agent for cancer therapy.
• To investigate the potential of the agent to induce ferroptosis in TNBC cells.
• To assess the immunogenic properties and anti-tumor immunity activation of the agent.

Main Methods:

• Development of a cRGD labeled magneto-liposome (T-LMD) co-encapsulated with iron oxide nanoparticles (IONPs) and doxorubicin (Dox).
• Evaluation of T-LMD uptake and cell death induction in MDA-MB-231 TNBC cells.
• Assessment of ferroptosis markers, immunogenic cell death (HMGB1 release), and ultrastructural changes via microscopy and biochemical assays.

Main Results:

• T-LMD demonstrated enhanced cellular uptake and induced significant ferroptotic cell death in TNBC cells.
• Ferroptosis induction was linked to the activation of iron/lipid metabolism pathways.
• T-LMD treatment led to HMGB1 release, indicating immunogenic cell death and potential anti-tumor immune activation.

Conclusions:

• The developed T-LMD agent effectively targets and induces ferroptosis in TNBC cells.
• T-LMD shows potential for augmenting anti-tumor immunity, offering a novel therapeutic approach for TNBC.
• This ferroptosis nano-inducer presents significant implications for the future treatment of triple-negative breast cancer.